Healthcare / Medical DevicesParis
$0.94
-0.07 (-7.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-15.0M · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
55.8x
↑ROE
-166.6%
↓Gross Margin
55.0%
↑Debt/Equity
1.76
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.5%
FCF CAGR
—
FCF margin
-9.0%
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $95.2M · net income $-58.2M · FCF $-8.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $95.2M | $95.2M | $101.2M | $93.0M | $196.6M |
| Net Income | $-58.2M | $-58.2M | $-43.3M | $-36.9M | $15.7M |
| EBITDA | $1.2M | $1.2M | $-19000.00 | $-11.5M | $51.7M |
| EPS | -4.03 | -4.03 | -4.03 | -2.85 | 1.26 |
| Gross Margin | 55.0% | 55.0% | 56.8% | 52.8% | 52.1% |
| Operating Margin | -66.5% | -66.5% | -35.9% | -40.2% | 17.8% |
| Net Margin | -61.2% | -61.2% | -42.8% | -39.7% | 8.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.76 | 1.76 | 0.78 | 0.53 | 0.32 |
| Current Ratio | 0.64 | 0.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.6M | $-8.6M | $-15.0M | $-49.2M | $-32.8M |
| Returns | |||||
| ROE | -166.6% | -166.6% | -53.8% | -29.7% | 9.6% |
| Valuation | |||||
| P/E | — | — | — | — | 10.79 |
| EV/EBITDA | 55.84 | 55.84 | — | — | 2.59 |
| P/B | 0.39 | 0.39 | 0.33 | 0.85 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | -5.9% | -5.9% | 8.8% | -52.7% | — |
| EPS Growth | 0.0% | 0.0% | -41.4% | -327.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.03 → -4.03
Residual
-26.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.